Industry
Biotechnology
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Insights
May 24, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Insights
May 21, 2024 | 7:00 pm
Portfolio Pulse from Benzinga Newsdesk
May 21, 2024 | 5:10 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 11:15 am
Portfolio Pulse from Benzinga Insights
April 26, 2024 | 12:00 pm
Portfolio Pulse from Benzinga Newsdesk
April 26, 2024 | 10:55 am
Portfolio Pulse from Benzinga Newsdesk
April 25, 2024 | 11:24 am
Portfolio Pulse from Vandana Singh
April 24, 2024 | 2:31 pm
Portfolio Pulse from Benzinga Newsdesk
April 24, 2024 | 11:51 am
Portfolio Pulse from Benzinga Newsdesk
April 24, 2024 | 11:02 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.